Innoviva, Inc.
17.57-0.12 (-0.68%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · INVA · USD
Key Stats
Market Cap
1.11BP/E (TTM)
30.82Basic EPS (TTM)
0.57Dividend Yield
0%Recent Filings
8-K
Innoviva Q2 revenue surges
Innoviva reported Q2 2025 revenue of $100.3 million, driven by steady $67.3 million in GSK royalties and surging $35.5 million in net product sales, up 64% year-over-year, fueled by IST's critical care antibiotics. The company launched ZEVTERA in the U.S. in July for MRSA infections, while zoliflodacin's NDA earned FDA Priority Review with a December 15 PDUFA date. Net income hit $63.7 million, bolstered by $24.4 million in favorable investment gains. Cash swelled to $397.5 million, yet R&D costs rose for zoliflodacin prep.
10-Q
Q2 FY2025 results
Innoviva's Q2 FY2025 revenue edged up 0.4% y/y to $100.3M, fueled by net product sales surging 64% y/y to $35.5M on stronger GIAPREZA and XACDURO demand, while royalties held steady at $63.9M. Gross margin dipped to 82.9% from 85.1% y/y amid higher costs, yet operating income fell 10.8% y/y to $48.8M, with R&D up sharply for zoliflodacin ahead of its December PDUFA. Diluted EPS swung to $0.77 from a $0.55 loss y/y, reconciling via if-converted method on $453M debt; YTD EPS of $0.24 aligns with 84.3M shares. Operating cash flow hit $92.7M YTD, lifting cash to $397.5M against $449M debt (2.5-2.125% rates, due 2025/2028) and full revolver availability. ZEVTERA launched in July; FDA accepted zoliflodacin NDA in June. Yet GSK's commercialization choices could crimp royalties.
8-K
Innoviva annual meeting results
Innoviva's stockholders at the May 19, 2025 annual meeting elected Derek Small, Mark A. DiPaolo, Jules Haimovitz, Sarah J. Schlesinger, and Pavel Raifeld to the board for one-year terms, with strong support exceeding 90% for each. They also approved executive compensation on a non-binding basis and ratified Deloitte & Touche as auditors for 2025. Board continuity solidified. No disruptions noted.
8-K
Q1 revenue up, but net loss
Innoviva kicked off 2025 with steady GSK royalty revenue of $61.3 million, while its specialty therapeutics arm surged 52% in U.S. net product sales to $26.4 million, driven by GIAPREZA, XACDURO, and XERAVA. Operating income climbed 61% to $41.4 million, yet a $78.8 million hit from investment fair value losses flipped the quarter to a $46.6 million net loss. Pipeline advances on track: zoliflodacin NDA filing slated for H1 2025; ZEVTERA U.S. launch mid-year. Investments buoyed the asset portfolio to $457.6 million.
10-Q
Q1 FY2025 results
Innoviva's Q1 FY2025 revenue climbed 14% y/y to $88.6M, fueled by net product sales surging 59% y/y to $30.3M on stronger GIAPREZA and XACDURO uptake, while net royalty revenue dipped 1% y/y to $57.8M from stable GSK respiratory assets. Gross profit hit $73.3M with margins expanding to 82.7%, and operating income rose 61% y/y to $41.4M as SG&A eased 10% y/y to $27.5M. Yet investment fair-value hits of $78.8M flipped the quarter to a $46.6M net loss, or ($0.74) diluted EPS—anti-dilutive shares excluded. Cash swelled 5% q/q to $319.1M, with $48.6M operating cash flow; $453.5M convertible debt matures 2025/2028 at 2.5%/2.125% rates, revolver not disclosed. ZEVTERA U.S. launch eyes mid-2025. Patent risks linger from GIAPREZA generic challenges.
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
FBIO
Fortress Biotech, Inc.
2.52-0.04
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
INSM
Insmed Incorporated
184.29+17.34
IVA
Inventiva S.A. - American Depos
4.16-1.11
IVBXF
Innovent Biologics Inc.
11.14-0.56
RVPH
Reviva Pharmaceuticals Holdings
0.59+0.01
TBPH
Theravance Biopharma, Inc.
14.17+0.07
TOVX
Theriva Biologics, Inc.
0.31-0.02
ZLAB
Zai Lab Limited
25.32-0.09